Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
Latest news
Date Title
<1m ago ENLINK MIDSTREAM : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
<1m ago MBAC FERTILIZER : Signs Senior Debt Extension Agreements, Receives Indication of a Commitment for Additional R$16 MM of Working Capital and Provides Update on Liquidity Initiatives
<1m ago FIRST HORIZON NATIONAL : Tennessee Bank to Expand in North Carolina With Acquisition of TrustAtlantic
<1m ago SOUTHERN : Georgia Power : named 2014 Investor-Owned Utility of the Year by Solar Electric Power Association
<1m agoDJKurds Set to Approve Kobani Plan
<1m ago OriginOil Granted Patent in China for its Core Extraction Invention
1m ago GLAXOSMITHKLINE : GSK sees first Ebola vaccine doses ready late this year
1m ago Plan ahead to lessen financial reliance on children later in retirement
1m ago PAZOO : Medical Marijuana Testing Laboratory Partner MA & Associates Hires Laboratory Technician, Facility Build-Out Currently Underway
1m ago PE INTERNATIONAL : and KieranTimberlake Report Wide Adoption of the Award-Winning Tally(TM) Tool for Life Cycle Assessment in Building Design
Latest news
Advertisement
Hot News 
DEUTZ : modifies forecast
BIC : 9 months 2014 Results
TAKATA : says to cooperate 'fully' after U.S. warning to drivers
URBAN&CIVIC : Granted Provisional Permission For Sainsbury's Store
PLAYTECH : Q3 Interim Management Statement
Most Read News
1d ago APPLE : How to Stop Apple Spying on Your Yosemite Searches
1d ago AMGEN : Third Point urges Amgen to consider breakup
1d ago TRUECAR : to Announce Third Quarter 2014 Financial Results on Thursday, November 6th
1d ago U.S. regulator expands warning over Takata air bags, more lawsuits filed
1d ago McDonald's CEO acknowledges image problems after tough results
Most recommended articles
<1m ago GLAXOSMITHKLINE : GSK sees first Ebola vaccine doses ready late this year
1m ago PRICE & TIME : EUR/USD Resuming The Broader Trend?
1m ago SPANISH BANKS SHOULD DO WELL IN ECB STRESS TESTS : De Guindos
1m ago GERMAN BANK HSH CURRENTLY SET TO PASS ECB HEALTH CHECK : sources
5m ago Siemens sees catch-up with rivals beginning in 2018
Dynamic quotes  
ON
| OFF